MAP4K3 and cancer: For example, hsa-miR-183-5p was found to inversely regulate PTPN4, serving as a therapeutic target to suppress the metastatic potential in NSCLC patients [32], and hsa-let-7c-5p was verified to prevent cancer metastasis by degrading its bridging hub ceRNA, MAP4K3 [33].